This finding was interpreted as related to energy dysregulation in MS, either reflecting a pathological impairment of intercellular creatine transport or reduced phosphocreatine consumption secondary to impaired function of brain creatine kinase (CK-B). The gene discussed is CKB; the disease is myeloid sarcoma.